JPMorgan Chase & Co. (NYSE:JPM) is a leading global financial services firm with operations in over 100 countries. It provides a wide range of services, including investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. As one of the largest banks in the United States, JPMorgan Chase competes with other major financial institutions like Bank of America, Citigroup, and Wells Fargo.On February 5, 2026, HSBC set a pri ...

On February 5, 2026, HSBC upgraded JPMorgan Chase & Co.'s stock (NYSE:JPM) from "Reduce" to "Hold." At the time, the stock price was $310.16. JPMorgan is a leading global financial services firm, offering a wide range of services including investment banking, financial services for consumers and businesses, and asset management. It competes with other major banks like Bank of America and Citigroup.Belpointe Asset Management LLC recently reduced its stake in JPMorgan by 4% during the third quarter, selling 1 ...

Core Viewpoint - Bio-Techne Corporation is a significant entity in the biotechnology sector, focusing on innovative tools and solutions for life sciences research and clinical diagnostics, competing with major players like Thermo Fisher Scientific and Danaher Corporation [1] Financial Performance - On February 4, 2026, Citigroup upgraded Bio-Techne's stock to a "Buy" rating at approximately $68.89, raising the price target from $70 to $80, indicating confidence in the company's growth potential [2] - Bio-Techne recently held its Q2 2026 earnings call, providing insights into its financial performance, revenue, profit margins, and strategic initiatives, which are crucial for understanding the company's current position and future outlook [3] Stock Performance - Currently, Bio-Techne's stock (TECH) is priced at $68.77, reflecting a 6.41% increase or $4.14, with a daily trading range between $61.70 and $69.92 [4] - Over the past year, the stock has fluctuated, reaching a high of $79.28 and a low of $46.01, indicating the dynamic nature of the stock market [4] Market Capitalization and Trading Volume - Bio-Techne's market capitalization is approximately $10.72 billion, with a trading volume of 3.59 million shares, reflecting the company's size and investor interest in its stock [5]

Citigroup upgrades LPLA to "Market Outperform" with a stock price of $376.33.Mutual of America Capital Management LLC increases its investment in LPLA by 116.6%, now holding shares valued at approximately $1.85 million.Other institutional investors, including Cullen Frost Bankers Inc. and Camden National Bank, have also raised their stakes in LPL Financial, indicating a positive market outlook.LPL Financial Holdings Inc. (NASDAQ:LPLA) is a prominent player in the financial services sector, providing a platf ...

Group 1 - KPN intends to issue a EUR 500 million Eurobond under its Global Medium Term Note programme to refinance existing debt and for general corporate purposes [1] - KPN is offering to repurchase GBP 400 million of its 5.00% notes due 2026 and up to GBP 300 million of its 5.75% notes due 2029 [2] - The transaction aims to proactively manage KPN's debt structure and reduce near-term refinancing requirements, with specific conditions for the Offers [3] Group 2 - BNP PARIBAS and Citigroup are appointed as Global Co-ordinators for the new bond offering, with several banks acting as Active Bookrunners and Dealer Managers [4] - KPN's announcement includes formal disclosures regarding the Eurobond and Tender Offer [5]

We recently published 10 Big Names Already Crushing This February. Lumentum Holdings Inc. (NASDAQ:LITE) was one of the top performers on Monday. Lumentum Holdings rallied for a second day on Monday, jumping 8.06 percent to close at $423.42 apiece as investors loaded portfolios ahead of its earnings outcome which came out shortly after market close. Earlier, Lumentum Holdings Inc. (NASDAQ:LITE) announced expectations of $630 million to $670 million in net revenues, as well as $1.30 to $1.50 diluted earni ...

Core Viewpoint - Gilead Sciences, Inc. (NASDAQ:GILD) is highlighted as one of the most profitable stocks on NASDAQ, with recent price target increases from Truist Securities and Citigroup indicating strong investor confidence in the company's future performance [1][3]. Group 1: Price Target Adjustments - Truist Securities raised its price target on Gilead Sciences to $145 from $140 while maintaining a Buy rating, citing revisions in estimates for the drug YEZTUGO and updates on upcoming launches [2]. - Citigroup also increased its price target for Gilead Sciences to $156 from $140, maintaining a Buy rating, as part of a broader Q4 preview for biopharmaceutical stocks [3]. Group 2: Company Overview - Gilead Sciences is a biopharmaceutical company focused on developing medicines for life-threatening diseases, including HIV, viral hepatitis, and cancer [4].

Tyler Crowe: It's 2026, and banking is booming. This is Motley Fool Money. Welcome to Motley Fool Money. I'm Tyler Crowe, and today I'm joined by longtime Fool contributors Matt Frankel and Jon Quast. It's that time again, folks, earning season, and we'll discuss earnings today, this proposal from the Trump administration to cap credit card rates because we are talking about banks. Of course, what Thursday show would be complete without talking about stocks on our radar. But first, when I opened up Bloomber ...

Citigroup Inc. (NYSE:C) is preparing for another round of employee layoffs expected in March, following approximately 1,000 job cuts executed earlier this month.The upcoming reductions are expected to primarily affect managing directors and other senior employees across business lines, according to a source cited by Reuters on Thursday, as the bank continues to streamline operations amid a broader restructuring effort.The latest cuts form part of a long-term plan announced two years ago to eliminate 20,000 ...

By Kanishka Ajmera and Rashika Singh Jan 22 (Reuters) - U.S. fintech stocks could gain an edge as Washington leans into a more populist, affordability-driven agenda ahead of ​the November 2026 midterm elections, analysts at Citigroup said in a ‌note. President Donald Trump's latest policy push is prompting investors to reassess parts of the financial ‌sector, with his emphasis on affordability potentially opening the door for fintech challengers instead of traditional lenders, the brokerage said. Compa ...